Illumina (ILMN) EVP/Clinical Genomics to Leave

November 29, 2016 5:00 PM EST

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

On November 27, 2016, Tristan Orpin, Executive Vice President, Clinical Genomics, notified Illumina, Inc. (NASDAQ: ILMN) that he would be leaving the company in January 2017. Illumina has identified and agreed to employment terms with a successor to Mr. Orpin, who will join the company in January 2017.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Management Changes

Add Your Comment